Israel Active

I reported previously when Israel’s Endospan received the CE mark for its Horizon stent graft system to treat Abdominal Aortic Aneurysm. It now also has received the CE mark for its Nexus Stent Graft System to treat Aortic Arch Disease.

I reported previously on the Nerivio Migra smart patch from Israel’s Theranica to provide migraine relief. Since then, Theranica has successfully completed a 12-center pivotal study of the patch and has raised $35 million for US FDA approval and beyond.

I reported previously on the PregSense wearable fetal monitor from Israel’s Nuvo. Renamed Invu,,multi-center trials produced fetal and maternal heart rates comparable to existing standalone cardiotocographs (CTGs). US FDA review is in progress.

I reported previously that the Aramchol treatment from Israel’s Galmed for Non-Alcoholic Steatohepatitis (NASH) had been fast-tracked by the US FDA. Latest trials show that twice-daily dosages of Aramchol significantly increased blood plasma levels.

The 3rd episode of Israel’s Weizmann in Focus, highlights that, since October, 7.3 million Americans have been sick with the flu virus with over 80,000 hospitalized. Weizmann Professor Ruth Arnon’s work has led to the development of the Universal Flu Virus, being trialed by Israel’s BiondVax.

An analysis of dietary data has shown that Israel has the lowest rate of diet-related deaths in the world.  The Global Burden of Disease study, published in UK’s The Lancet, reported that in Israel, just 89 people out of every 100,000 die each year in deaths related to poor-quality diet.

Israel’s Anlit has launched a probiotics chew targeting women's health. Feminine Probiotics contains a blend of six different strains of live probiotic bacteria plus cranberry extract to support genitourinary tract health. It comes as a vanilla-cranberry flavored chew that melts in the mouth.

13-year-old Hila Amram received a new liver and pancreas at Petah Tikva’s Schneider Children's Medical Center. The double transplant saved her life and freed her from insulin dependence. The op was even more complex due to the donor’s internal organs being reversed - a rare anomaly.

Biotech eXithera is a portfolio company of Israel’s Clal Biotechnology. It has developed an anti-coagulant which has successfully completed Phase 1 trials. The treatment delays coagulation rather than prevents it and its effects cease quickly when the treatment stops.

I reported previously on the brain analysis system developed by Israel’s elminda. The EU has just awarded elminda a 2-year grant through its Horizon 2020’s phase 2 program. It will help elminda develop and trial its BNA-PREDICT product for depression.